Drug Delivery · 2015 · 43 citations · 38 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyDrug DeliveryCancer NanomedicineColorectal CancerDrug EncapsulationNanocarriers For TherapeuticsNanomedicinePharmacokinetics Of Anticancer DrugsChitosan BiomaterialsChitosan NanocarriersChitosan-based BiomaterialsChitosan-based Delivery SystemsChitosan-based PolymersMicrosphere DeliveryMicrosphere FormulationsMinimum Inhibitory Concentration Determination
PURPOSE: Microspheres of chitosan (CS) cross-linked with polyethylene glycol (PEG) were prepared by emulsion-cross-linking followed by the solvent evaporation technique. The formulations were characterized and subjected to in vitro and in vivo tests to assess cell growth, changes in cell morphology, and activities by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on human HT-29 colon cancer cell-lines. METHODS: In vivo activity was evaluated for dimethyl hydrazine-induced colorectal cancer in albino male Wistar rats. Biochemical and histological parameters were evaluated to understand their effectiveness for colon cancer therapy. RESULTS: value required to stop the growth or death of colon cancer cells from the colonic dysplasia in Duke's stage A. Significant reduction in tumor volume and multiplicity was observed with increased levels of liver enzymes in animals when treated with standard 5-FU formulation compared with 5-FU loaded microspheres. Elevated levels of serum albumin, creatinine, leukocytopenia, and thrombocytopenia were observed in animals for the standard 5-FU formulation. CONCLUSION: The PEG cross-linked CS microspheres of this study slowly released 5-FU up to 24 h to colonic region and enhanced the antitumor activity.
38
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Robert C. Hastings · JAMA · 1996 · 2.4K citations